Marc is passionate about creating novel biomedical ventures. He is a co-founder at Rejuversen AG, Ninevah Therapeutics SL and Senolytic Therapeutics Inc. Currently, Marc is a Board member or strategic advisor at Ninevah Therapeutics, Retinset Therapeutics, Cyclomed, Gate2Brain, Cebiotex and Origen Ventures. He is a co-founder and Partner at Chasing Science, an early-stage biomedical venture builder.

Marc gained a DPhil in Biochemistry from the University of Oxford, a PDL executive degree at Harvard Business School, a M.Sc. in Chemical Engineering and a B.Sc. in Chemistry from IQS (Barcelona).